Assuming that all diseases have in common the perturbation of cellular redox environment, developing SOD mimics still seems to be the appropriate strategy for the design of potent redox-active therapeutics.
Introduction
The necessity of SOD enzymes for all aerobic life [1, 2] led to the development of SOD mimics as therapeutics [3] . The macrocyclic structure of a porphyrin ring, by the analogy to the structure of the critical porphyrin-containing proteins, such as hemoglobin, myoglobin, nitric oxide synthases and cyt P450 family of enzymes, provides limitless stability to a metal complex and preserves II P redox couple is within the range of þ100 to þ 500 mV vs NHE. Such E 1/2 values indicate that SOD mimics are mild oxidants and reductants/antioxidants and that their reduction potentials are biologically compatible and allow them to couple with numerous other biological targets. Yet, there is another side of dismutation process. The 2nd step (while antioxidative in its nature with regards to O 2 d À ) produces an oxidant, H 2 O 2 . The SOD enzymes and their mimics may in turn be only viewed as anti-oxidative defense when (under physiological conditions) are coupled with multiple H 2 O 2 removing systems. It explains why in numerous in vivo reactions (oxidation of thiols, ascorbate, lipids, NADPH, NADH, see below) MnP acts as pro-oxidant, while still GENERATING therapeutic EFFECTS. Thus the additional distinction must be made here between the actions of redox-active compounds and therapeutic effects observed. Please note that MnPs with very negative E 1/2 o 0 mV vs NHE (very electron rich such as MnTBAP 3 À or MnTSPP 3 À ) are fairly redox-inert and cannot be reduced in a 1st step with O 2 d À , but can act as anti-oxidants (reductants) during oxidation with strong oxidants (such as ONOO À , ClO À , lipid reactive species). Since they are electron-rich, and oxidation with those species involves their binding to
Mn site, such reactions are less favored than those with electron-deficient Mn porphyrins (such as MnTE-2-PyP 5 þ ) with E 1/2 in between þ 100 and þ500 mV vs NHE [7] .
Note, also that MnPs with E 1/2 4 þ450 (very electron-deficient, Mn II Br 8 Mn(III)-and Fe(III) corroles employ metal þ 3/þ 4 redox couple also [8] . In turn, in a 1st step those metal sites reduce O 2 d À while undergoing oxidation to M(IV) complex, whereas in backward reaction they get reduced with O 2 d À (and restored as catalysts) (see [3] for details). Regardless of which metal redox couple is used ( þ 3/þ 2 or þ3/ þ 4), O 2 d À only cares if the metal easily accepts electron from and donates the electron to it, thus operating at E 1/2 value that is around the midway potential between the oxidation and reduction of O 2 d À ; consequently both steps of dismutation are facilitated to a similar extent. That indeed is true, the E 1/2 ranges between þ440 and þ 470 mV vs NHE for Mn(III) biliverdin analogs, while E 1/2 ¼ þ468 and þ 480 mV vs NHE for Br 8 Mn II TM-3-PyP 4 þ for Br 8 Mn II TM-4-PyP 4 þ [9] .
integrity of the metal site where all actions occur. Consequently, porphyrin appears to be the most appropriate ligand for an SOD mimic. Further, the porphyrin structure allows for limitless modifications whereby the redox property, bioavailability and toxicity could be optimized. Over years in search for the best therapeutics, metalloporphyrins with high k cat (O 2 d À ) reaching that of SOD enzyme and with high stability towards the loss of Mn, have been synthesized and characterized. Such properties give them the advantage over other classes of SOD mimics. Most recent research indicate that SOD-like activity parallels ability of MnPs to undergo other reactions (such as ONOO À reduction) and their therapeutic efficacy. None of the reactions appear specific to MnPs. For additional insight see also other articles in Antioxidant & Redox Signaling 2014 Forum Issues on "Superoxide dismutases" (vol. 20/10) and "SOD therapeutics" (vol.20/15).
O 2 d À dismutation process
The dismutation process consists of two steps indicated below for Mn porphyrin-based SOD mimics. It is critical to note that: (i) SOD enzyme or MnP-based mimic acts as a (pro)oxidant in a 1st step, and as an anti-oxidant in a 2nd step, whereby closing the catalytic cycle, and (ii) an oxidant, H 2 O 2 , is produced in a 2nd step. Under physiological conditions it is taken care of. Thus, H 2 O 2 is either dismuted to O 2 and H 2 O 2 , or H 2 O 2 is reduced to H 2 O, with enzymatic systems such as catalases, glutathione peroxidases (GPx), peroxiredoxins, etc. Therefore both SOD and its mimic could Scheme II. SOD mimics were designed in a process where the kinetics and thermodynamics of O 2 d À dismutation catalyzed by superoxide dismutases were mimicked. The kinetics of the catalysis O 2 d À dismutation relates to the electrostatic facilitation of the approach of anionic O 2 d À towards the metal site. In the case of enzyme the anionic superoxide is pulled towards the metal site through the tunnel of amino acids with cationic residues. Those MnPs which have cationic charges on periphery are $ 2 or 2.5 orders of magnitude faster catalysts than those which are either neutral or anionic at the periphery, respectively. The thermodynamics relates to the redox properties of the metal site (described with metal-centered reduction potential, E 1/2 ) which would allow Mn to equally easily accept electron from one O 2 d À and give it to another O 2 d À . Cationic compounds with E 1/2 for Mn III P/Mn II P redox couple around the E 1/2 of SOD enzymes ( $ þ300 mV vs NHE) were synthesized and demonstrated to efficiently catalyze O 2 d À dismutation in aqueous solution with high rate constants. In addition, they are extremely stable complexes towards the loss of Mn. Such E 1/2 of SOD enzyme and its mimics sits around the midway potential between the E 1/2 for O 2 d À reduction at þ890 mV vs NHE and its oxidation at À 180 mV vs NHE. In turn, it allows equal facilitation for both steps of dismutation process [3, 9] . Indeed both steps occur with the same rate constants with SOD enzyme as was demonstrated for its mimic, MnTE-2-PyP 5 þ [10] .
The most powerful SOD mimics belong to the class of Mn(III) ortho (N-substituted pyridinium-2-yl)porphyrins. They possess both favorable electrostatics, as they bear 4 positive charges at the periphery to attract O 2 d À , and favorable thermodynamics, E 1/2 $ þ200 to þ450 mV vs NHE. Among them the ortho, meta and para pyridyl MnPs which are β-halogenated (with chlorines at β positions of pyrrole rings, see Scheme IV) possess the highest k cat (O 2 d À ), close to that of SOD enzymes; yet they are the least stable. Adapted from [3] .
be considered an antioxidative defense only when coupled to H 2 O 2 removing systems. Growing data indicate that in cancer such systems fail. Reports indicate downregulation or inactivation of enzymes such as GPx and peroxiredoxin, while up-regulation of SOD during cancer progression [4] [5] [6] . In turn, H 2 O 2 gets accumulated and used by cancer cell for its proliferation; under such conditions both SOD and its mimic will increase oxidative stress and cannot be anymore considered an antioxidative defense [3, 5, 6] . 
Design of SOD mimics

Structure-activity relationships, SAR, for mimicking SOD enzymes
See Scheme VI.
Mn porphyrin-based non-SOD mimics
See Scheme VII.
Fe porphyrin-based SOD mimics
See Scheme VIII.
Reactivities of MnPs towards diverse low-molecular weight reactive species
The reactivity of ortho Mn(III) N-substituted pyridylporphyrin towards a whole spectrum of reactive species with corresponding rate constants (estimated based on reactions of MnTE-2-PyP 5 þ ) is
Scheme III. The design of SOD mimics occurred through phases I to IV. The unsubstituted electron-rich MnT-4-PyP þ has E 1/2 value for Mn III P/Mn II P redox couple of À 200 mV vs NHE which is too negative (more negative than E 1/2 ¼ À180 mV vs NHE for O 2 d À oxidation) and precludes its reduction (along with O 2 d À oxidation) to start the 1st step of dismutation process. In addition, there is no electrostatic facilitation; subsequently it has no SOD like activity, log k cat (O 2 d À )¼ 4.53. In order to decrease metal center electron density to enable its acceptance of electron and reduction with O 2 d À , the alkyl groups were added to pyridyl nitrogens in Phase I; subsequently nitrogens became cationic and withdrew the electron density from Mn site. In turn, Mn becomes electron-deficient and prone to be reduced at biologically feasible Ε 1/2 of þ 60 mV vs NHE, which results in a modest log k cat (O 2 d À ) ¼6.58. Such rate constant is still $ 3.5 orders of magnitude lower than that of SOD enzyme. Shifting nitrogens from para (4) positions to ortho (2) positions in Phase II moves positive charges closer to Mn site, which enhances both the electron-withdrawing effects and the attraction of anionic superoxide to cationic Mn porphyrin. In turn, E 1/2 of MnTM-2-PyP 5+ is increased for another order of magnitude, log k cat (O 2 d À )¼ 7.79. Very importantly alkyl chains in ortho positions are stuck above or below the porphyrin plane and suppress the interaction of MnP with nucleic acid [11] . Such interaction demonstrated with planar para MnTM-4-PyP 5 þ prevent its SOD-like activity and may impose toxicity. Ortho isomers exist as 4 atropoisomers which all have the same E 1/2 and same log k cat (O 2 d À ), but likely have different biodistribution [12] . Once the knowledge on key ortho impact has been gained, ortho N-ethylpyridyl analog MnTE-2-PyP 5 þ and its di-ortho N,N′-diethylimidazolyl derivative, MnTDE-2-ImP 5 þ , were synthesized in Phase II and Phase IIa and are among the most frequently studied compounds both in vitro and in vivo. Both compounds are pentactionic and thus highly hydrophilic. Initial studies suggested that, by increasing lipophilicity, we should be able to enhance their accumulation within organs and cells and mostly so brain. While cationic charge is a driving force, lipophilicity is another major factor that affects their transport across the blood brain barrier and mitochondrial accumulation and in turn their therapeutic efficacy [80] [81] [82] 89] . The lipophilicity was addressed in Phase III. Several lipophilic compounds have been synthesized. MnTnHex-2-PyP 5 þ (~6,500-fold more lipophilic than MnTE-2-PyP 5+ ) has been the most frequently studied in vitro and in vivo. The longer the hydrophobic alkyl chains the higher their micellar properties and the higher ability to damage lipid membranes. This is however outbalanced with the much higher accumulation of MnTnHex-2-PyP 5 þ within cell; in turn, up to 120-fold lower doses are needed for the efficacies identical to those produced by hydrophilic MnTE-2-PyP 5 þ . This further allowed for a wider therapeutic window for the hexyl than for ethyl analog [13] . The micellar property and in turn toxicity was suppressed by $ 4-5-fold relative to MnTnHex-2-PyP 5 þ when polar oxygen atoms were introduced into alkyl chains: MnTnBuOE-2-yP 5 þ was synthesized in Phase IV [14] and has been aggressively developed towards clinic. Researchers need to pay attention to the type of rate constants they refer to. Immediate translation of data from aqueous solutions to cellular and animal models is not straightforward and often requires substantial insight into extremely complex chemistry of those redox active drugs, their biodistribution (affected by their lipophilicities, polarities, charge, size and bulkiness) at sufficient concentrations and at targeted location [3, 5, 9, 15, [22] [23] [24] .
Reactivity of MnPs towards cellular reductants -thiols, ascorbate and tetrahydrobiopterin
The interactions of Mn(III) ortho N-substituted pyridylporhyrins with cellular reductants seems to play critical role in the biology of MnPs, in great part due to high levels of cellular reductants. Such interactions have been explored in aqueous solutions, in vitro and in vivo and are depicted in Schemes IX-XIV [3, 18, 30, [40] [41] [42] [43] [44] Ps carry one þcharge on Mn center. SARs have been initially established for Mn porphyrins and later proven to have wider applicability to any redox active metal complex (Scheme VIB). As compared to cationic MnPs, the $ 2-2.5 orders of magnitude lower k cat (O 2 d À ) was determined with neutral or anionic compounds than with cationic MnPs, where either no attraction exists or anionic O 2 d À is repulsed from anionic porphyrin. The additional importance of such SARs lies in the fact that the magnitude of the interactions of SOD mimics with other reactive species (thus far explored, Schemes IX-XIV), and their therapeutic effects are directly proportional to their SOD-like activity; in turn SAR established for SOD-like activity, can offer best guidance for the development of powerful therapeutics. Compounds which dismute O 2 d À with rate constants lower than that for
, are not mimics of SOD. A number of Mn porphyrins with no SOD-like activities reportedly demonstrate beneficial therapeutic effects in vitro and in vivo models of diseases (Scheme XXV). Such data suggest that mechanism of action, other than SOD-like, may be operative [4] . Adapted from [16] . (B) Structure activity relationships, SARs, relates E 1/2 to log k cat (O 2 d À ) for all compounds irrespectively of their electrostatics, their size and shape and type of redox couple involved. The blue curve relates to all compounds irrespective of the type of redox couple involved: either Mn(III)/Mn(II) or Mn(IV)/Mn(III). The O 2 d À does not care which type of redox couple is involved, as long as the magnitude of E 1/2 is adequate. The red dashed curve relates to the compounds which operate via Mn(III)/Mn(II) redox couple, while the green one relates to compounds that utilize Mn(IV)/Mn(III) redox couple for O 2 d À dismutation. While we have not explored it further, the maximum seems to be shifted right for compounds which use Mn(IV)/Mn(III) redox couple; therefore the dashed curves are suggested. The larger deviation from the plot is demonstrated with compounds which have unfavorable electrostatics (anionic, bulky compounds). The largest deviation is seen with non-metal-based SOD mimics such as nitroxides. When the E 1/2 is very negative, left arm of bell-shape curve, the reduction of Mn III P to Mn II P is a rate limiting step in O 2 d À dismutation. As the E 1/2 increases, reaching maximal log k cat values, both steps of dismutation become similar and offer similar thermodynamics for the dismutation process, such conditions favor high k cat (O 2 d À ). Once the electron-density of Mn center gets overly reduced, E 1/2 of Mn(III)/Mn(II) redox couple 4 þ450 mV vs NHE, the compound becomes stabilized in Mn þ 2 oxidation state (the right arm of the bellshape curve). The consequence of this is that Mn(II) porphyrins are unstable (Mn gets easily lost) and are therefore not prospective therapeutics. Under such conditions the 1st and 2nd steps of dismutation process are reversed. With Mn(II) porphyrins, as the E 1/2 becomes too positive, the 1st step of dismutation (oxidation of Mn II P to Mn III P and reduction of O 2 d À to H 2 O 2 ) becomes unfavorable and rate limiting; in turn the k cat (O 2 d À ) decreases again (the right arm of bell-shape curve). Adapted from [3] .
role of ONOO À in the chemistry and biology of MnPs has been increasingly appreciated (Scheme XV).
Differential (therapeutic) effects of MnPs on cancer vs normal cell
Differential effects of MnPs in cancer vs normal cell have been shown and reported in a number of cellular models (Schemes XVI and XVII).
Differential (therapeutic) effects of MnPs on cancer vs normal tissue in animal models
Differential effects of MnPs in cancer vs normal cell have also been shown and reported in a number of animal models. Radioprotection of salivary glands and mouth mucosis in non-tumor bearing mice receiving daily MnTnBuOE . Such treatment has a chance to reduce prostate radiation-induced ED which would encourage the men with prostate cancer, who have thus far been reluctant, to undergo radiation therapy. Scheme XVII describes the data on the radioprotection of a normal brain in non-tumor bearing mice and radiosensitization of brain tumor in a mouse sc glioma xenograft model [53] (Scheme XVIII).
Impact of MnPs on cellular transcription
At present stage of our knowledge, the direct reactions of MnPs with thiols of transcription factors, such as NF-κB or Keap1/Nrf2, and/or coupled to other species, may present major contributions to the therapeutic efficacy of MnPs. In addition to direct reactions, the indirect impact of MnP on NF-κB via scavenging reactive species, which would have otherwise signaled its activation, cannot be ruled out [53] (Scheme XIX).
Suppression of cellular energetics of a cancer cell with MnPs
S-glutathionylation of complexes I, III and IV of mitochondrial electron transport chain with subsequent inactivation of complexes I and III and suppression of ATP production of lymphoma cells when those were treated with MnP/dexamethasone was reported by Tome's group [45] . In addition to the radiosensitizing actions of MnPs, such chemosensitization may further contribute to their anticancer effects [3] (Scheme XX). 
MnPs as inducers of adaptive responses via (pro)oxidative mechanism(s)
Oxidative modification of Keap1 thiols with subsequent activation of Nrf2 and upregulation of endogenous antioxidative defenses was shown with another class of SOD mimics, M40403 [72] . Such data along with results shown in Scheme XXI strongly suggest that MnP could act in a similar manner as inducer of endogenous antioxidative defenses. The upregulation of different SOD enzymes in rat kidney ischemia/reperfusion injury strongly suggests that MnP does not act as SOD mimic. A lipophilic analog, MnTnHex-2-PyP 5 þ was tested. Bioavailability -pharmacokinetic studies Scheme XXIII.
Targeting mitochondria
Due to the critical role mitochondria has in all organisms, the compounds that are able to cross two mitochondrial membranes and preferentially target its matrix have been sought. Excellent work has been done on the basics of mitochondrial transport by Skulachev's and Murphy's groups [87, 88] . Based on their research, the essential properties of mitochondrially-targeted drug are identified to be cationic charge and lipophilicity. Most efficacious MnPs bear penta-cationic charge. Moreover the lipophilic analogs bear long hydrophobic substituents. Such facts justified extensive studies of mitochondrial accumulation [80] [81] [82] 89] . We have demonstrated that MnPs accumulate in mouse heart mitochondria, and those that are more lipophilic do so to a higher extent than the hydrophilic compounds, such as MnTE-2-PyP 5+ . Lipophilic MnTnHex-2-PyP 5 þ and MnTnBuOE-2-PyP 5 þ were found in mouse
(8)
(10)
brain mitochondria also. We were not able to measure the hydrophilic MnTE-2-PyP 5 þ in brain mitochondria as its levels were below LCMS/MS detection limit [90] . The mitochondrial/cytosolic ratios of MnTnHex-2-PyP 5 þ and MnTnBuOE-2-PyP 5 þ in heart and brain mitochondria are similar [68] . The remarkable impact of lipophilicity on the accumulation of cationic MnPs in mitochondria relative to cytosol of Saccharomyces cerevisae is shown in Scheme XXIV.
Diminishing toxicity
While most of the requirements for a good MnP-based redoxactive drug are met, lowering MnP toxicity remains a challenge. Since, most but not all MnPs cause acute toxicity due to the blood pressure drop (BPD) , cross blood brain barrier to significant extent and tend to damage membranes and become toxic at higher levels. Therapeutic window needs to be identified for each MnP. The most frequently studied compound with excellent safety/toxicity profile, MnTE-2-PyP 5 þ , [92] has two "weaknesses": (i) low transport across the blood brain barrier which reduces its chances to be used for treatment of CNS injuries, and (ii) short patent life of only 4 years which precludes Pharma's investment into its development.
Therapeutic effects
What controls the magnitude of MnPs therapeutic effects?
Bioavailibility and redox properties control therapeutic effects. Redox properties are best described with E [35] . Reduction of lipid reactive species with MnP: while those reactions have not been quantified, the indirect evidence suggests that Mn III P scavenges lipid reactive species whereby preventing lipid peroxidation. However, that happens only in the presence of cellular reductants. When the low-density lipoproteins were exposed to low flux of ONOO À , the 5 mM MnTE-2-PyP 5 þ , MnTnOct-2-PyP 5 þ and MnTBAP 3-prevented lipid peroxidation, i.e. the formation of cholesteryl ester hydroperoxide in the presence of uric acid. The most lipophilic MnTnOct-2-PyP 5 þ was the most efficacious and $ 2-fold better than MnTE-2-PyP 5 þ . The MnTBAP 3À was $ 2-fold less efficacious than MnTE-2-PyP 5 þ . Also α and γ tocopherol were spared. Yet in the absence of uric acid MnPs acted as a pro-oxidant; the consumption of tocopherols was potentiated and more so with more redox-active cationic MnPs than with MnTBAP 3À [36] . Similar impact of MnTE-2-PyP 5 þ on lipid reactive species has been suggested in another study also [37] .
Hypochlorite reduction with MnP. While only preliminary data are collected on MnTalkyl-2-PyP 5 þ , the reactivity towards hypochlorite seems to be of the same order of magnitude as organelles) and is in turn controlled by lipophilicity, polarity, charge, size, shape and bulkiness of a molecule. The reactivities and in turn therapeutic effects are further controlled by the levels or reactive species in immediate neighborhood of MnPs. Based on all said, the best strategy in the design of an excellent therapeutic able to restore normal physiological redox environment may be to: (i) assure high metal/ligand stability, and in turn provide integrity of metal site; (ii) target as high as possible SOD-like activity; (iii) maintain positive charges to enhance electrostatically the reactions of MnPs with predominantly anionic reactive species, while enhancing lipophilicity. Enhanced lipophilicity would result in (iv) enhanced accumulation of MnPs at all sites abundant with anionic phosphates such as mitochondria and brain. Importantly, the efforts need to be continuously invested in (v) minimizing toxicity of MnPs (Scheme XXV).
Distinction must be made between anti-and pro-oxidative reactions and anti-and pro-oxidative therapeutic effects See Scheme XXVI.
SOD mimics -the story continues
The perfect therapeutic should promote adaptive responses and help our body with upregulation of our own endogenous antioxidative defenses. The most obvious case of such adaptive response is demonstrated during regular physical exercising. Increasing number of reports support pro-oxidative actions of MnPs, nitroxides and flavonoids which result in adaptive responses. During 2 decades of research, we have gone a long way from initially viewing MnPs as antioxidants exclusively (SOD mimics) to considering them (pro)oxidants. Interestingly enough, with data right in front of our noses, it took us a long time to consider all aspects of O 2 d À dismutation process. The incorrect viewing of SOD enzyme and its mimic as antioxidants lies in 2 facts. Firstly, the two reactions involved in a dismutation process require a compound to be equally good anti-and pro-oxidant (Scheme I). Secondly, the dismutation process produces an oxidant, H 2 O 2 . In turn, the SODs and their mimics can only be considered antioxidative defenses if H 2 O 2 is removed rapidly in conjunction with catalases or peroxidases. Such considerations help us understand that, based on identical thermodynamics of metal centers and depending upon the cellular redox environment (levels of oxidative stress) plethora of reactions are possible with SOD enzymes and MnPs. Yet, due to steric hindrance imposed by large protein structure such reactions of SODs occur, if at all, with orders of magnitude lower rate constants as compared to their small molecular-weight mimics.
A number of other issues need to be addressed as the MnPs advance towards Clinic. How long the treatment with MnP, following injury, should last? Will we be able to ever restore the physiological redox status, or as soon as the therapy is discontinued some level of inflammation will be re-established. Studies on CNS indicate that the longer the treatment lasts, the longer the reduction in stroke volume post-injury was demonstrated [93] . What are the therapeutic concentrations of MnPs at the sites of injury? We have only marginal knowledge how much of MnP we need in target tissues. It seems that $ 30 nM brain levels afford protection with MnTnHex-2-PyP 5 þ in a stroke model [94] . Yet, we do not know if lower levels would produce such effects also. Clarification of such issues is costly but eventually will be needed. is eliminated) in Scheme A, while it is generated in Schemes B and C. The GSSG species can exchange thiol spontaneously with RSH whereby glutathionylated protein is formed. Reactivity towards thiols may predominate in therapeutic effects of MnPs. Studies on CNS injuries, diabetes and cancer show that oxidation of cysteines of p50 and p65 subunits by MnP (enhanced with dexamethasone as a producer of H 2 O 2 ) suppresses/precludes the NF-κB activation and in turn suppresses inflammation rescuing the diseased cell and/or precluding the survival of cancer cell [45] [46] [47] [48] [49] . In addition S-glutathionylation of cysteines of complexes I, III and IV and subsequent inactivation of complexes I and III of mitochondrial respiration may play key role in reducing ATP levels in tumor cell whereby suppressing tumor growth (see Scheme XX) [46] . The impact of MnP on ATP levels via glycolysis has been demonstrated also [50] [3, 43] . MnP will in vivo likely couple with endogenous ascorbate due to its high levels. Yet therapeutic effects may be enhanced with exogenous ascorbate [42, 44] . The system MnP þ ascorbate, with regards to its mechanism of action, resembles to other major anticancer therapies which generate H 2 O 2 (radiation and chemotherapy) where MnPs act as radio-and chemosensitizers [3, 47, 53] See also Schemes XVI-XVIII. [54] . Cycling with BH 4 could result in tumor growth suppression via inhibition of its angiogenesis [54] . Recovery of MnP catalyst may lead to H 2 O 2 production via Eq. (7). Alternatively, BH 4 may be oxidized with high-valent, highly oxidizing O=Mn imidazolyl porphyrins suppress inflammatory processes in normal cell and cancer cell to a different extent but through identical actions -modifications of thiol-based signaling pathways. As SOD potency relates to the therapeutic effects of Mn porphyrins we alternate between describing them as SOD mimics or redox active therapeutics.
Scheme XV. SOD-like activity parallels other reactions of MnPs thus far studied as exemplified here with reduction of ONOO À , oxidation of ascorbate and catalysis of H 2 O 2 dismutation by MnP. Why potent SOD mimics are effective scavengers of other species and why in turn they may still be the most prospective therapeutic agents (assuming they are optimized for bioavailability and toxicity)? 
has been obtained at E 1/2 for Mn III P/Mn II P of $ þ200 to þ 450 mV. The values of E 1/2 Z þ400 mV stabilize Mn in þ 2 oxidation state and either Mn II P or a very weak Mn III P complex is formed. At values of E 1/2 r þ 100 mV Mn is stabilized in þ3 oxidation state to such extent that it does not favor reduction to Mn II P complex in a 1st
step in order to start the O 2 d À dismutation. The E 1/2 of around þ 200 to þ400 mV vs NHE is around the E 1/2 of SOD enzymes where both steps of dismutation process occur with similar rate constants and are thus similarly thermodynamically favored. The E 1/2 describes the magnitude of metal electron density which in turn reflects electron density of porphyrin ligand. E 1/2 of metal center thus relates to the protonation equilibria at all porphyrin sites (at pyrrolic nitrogens of porphyrin ligand and at waters axially ligated to metal site). Two such equilibria have been quantified at: (i) 3rd inner pyrrolic nitrogen of metal-free porphyrin, pK a3 [H 3 P þ ↔H 2 P þH þ ], and (ii) at 1st axially bound
. The inversed linear relationship exists between E 1/2 and pK a(ax) and pK a3 each: the higher the propensity of MnP to be reduced (the higher the E 1/2 ), the more-electron-deficient MnP is and less strongly it keeps its axial waters, thus easier (at lower pH) the proton is released and in turn the lower is the pK a(ax) . The same is true for pK a3 . The more pyrrolic nitrogen favors the proton association (the higher the pK a3 ), the more electron-rich nitrogen is. In turn, such electron rich porphyrin ligand favors the formation of a stable complex with Mn. That means the higher the pK a3 the less positive is the E 1/2 for Mn III P/Mn II P redox couple.
The consequence of such relationships is that the more electron-deficient the Mn complex is (lower the pK a3 ), in addition to aqua ligand, the more it would favor binding different ligands, such as ONOO À , ClO À , CO 3 . À and H 2 O 2 . The binding of these species comprises the 1st step in their reductions. This further explains why the rate constants for the reduction of ONOO À or ClO À and H 2 O 2 dismutation are related to the E 1/2 of the Mn III P/Mn II P redox couple though it is not involved in such reactions (Scheme XII). As
is proportional to both log k red (ONOO À ) and log k cat (H 2 O 2 ) as shown in plots A and C. Importantly, the E 1/2 of electron transfer which follows the binding of those species, and involves Mn þ 3/þ 4 oxidation states (Eq. (1)), appears to be nearly identical for all MnPs [6, 59] . In vivo, the 2nd step may preferentially involve two-electron electron transfer between Mn þ 2 and Mn þ4 oxidation states (Eq. (4)). Under such conditions, the differences in E 1/2 for the Mn III P/Mn II P redox couple will affect the E 1/2 of O¼ Mn IV P/Mn II P redox couple. The ability of MnP to couple with ascorbate (plot B), catalyzing its oxidation follows the same trend as described for ONOO À and H 2 O 2 , as binding of ascorbate is involved in a 1st step of ascorbate oxidation. The deviation from the linearity has been demonstrated with compounds which have bulky pyridyl substituents (encircled in plots B and C). While not showed in plot A, the deviation from linearity has been seen also [7, 10] .
Scheme XVI. Differential therapeutic effects of MnP/ascorbate system on cancer (cervix cancer HeLa) vs normal cell line (human dermal fibroblasts, NHDF). MnP stands here for MnTE-2-PyP 5 þ . The differential therapeutic effect is based on differential redox environment of cancer vs normal cell [5, 60] . Growing insight into the biology of cell and redox chemistry of MnPs taught us that we can take advantage of the rapid coupling of MnP with abundant cellular reductants [3, 6, 17, 41, 44, 51, 52] . Thus far we have shown that the catalytic oxidation of ascorbate with MnP (coupled to oxygen, Scheme XII) would enhance peroxide levels and could kill cancer without affecting much normal tissue [3, 46] . The reason lies in fact that cancer is frequently low in H 2 O 2 -removing systems (catalases, GPx, peroxiredoxins) and cannot cope with additional increase in H 2 O 2 levels [4] [5] [6] 60] . This reasoning is the same as the one behind the use of other H 2 O 2 -producing strategies: radio-and chemotherapy. Oxidation of ascorbate at the expense of endogenous metalloproteins has already been employed in clinical trials in patients with pancreatic cancer [61, 62] . The use of Mn porphyrin, MnTE-2-PyP 5 þ and analogs of similar redox properties (MnTnHex-2-PyP 5 þ , MnTnBuOE-2-PyP 5 þ ), optimized for ascorbate oxidation, has been reported by us [3, 6, 41, 43, 44] and subsequently by others to bear therapeutic potential [40, 42, 63] . (MnP) [53] . (B) Histological evaluation of myelinated axons in the corpus callosum. Representative images of toluidine blue-stained mid-sagittal corpus callosum tissue were imaged by brightfield microscopy (n ¼3 mice/group). Groups studied were (1) Saline, (2) MnP (3) Saline / radiation (RT), and (4) MnP/RT. Toluidine blue-stained mid-sagittal corpus callosum tissue were imaged by brightfield microscopy (n ¼3 mice/group). Three images from each mouse underwent automated axon counting that is quantitated in the box graph with 95% confidence intervals. ANOVA analysis of the group resulted in significant differences among the groups (p¼ 0.040). Scheme XIX. Impact of MnPs on cellular transcription. The reactions of MnPs were thus far explored with respect to several transcription factors, NF-κB, AP-1, SP-1, HIF-1α (see also Scheme XIV) [48] . MAPK/ERK pathway has been implicated also [41] . Oxidation of cysteine residues of p50 and p65 subunits of NF-κB by MnPs/H 2 O 2 (the prooxidative actions of MnPs) prevents the activation of NF-κB, and in turn suppresses excessive inflammation and thus produces therapeutic effects which we identify as antioxidative [3] . Data obtained by us on MnPs (Scheme XXI) [66, 67] and others on a member of other class of SOD mimics, Mn(II) cyclic polyamines, M40403 [68] , suggest the impact of MnPs on the activation of Nrf2. Upon oxidation of redox sensitive cysteines of Keap1, Nrf2 transcription factor is activated, which results in upregulation of endogenous antioxidative defenses [67, 68] . Nitroxides were shown to activate that pathway also [69] [70] [71] . It may be mechanism of actions of flavonoids also [70, 71] (see also Scheme XX).
Scheme XX. MnP inactivates complexes I and III via their S-glutathionylation when combined with dexamethasone in lymphoma cellular model. MnTE-2-PyP 5 þ was tested in lymphoma cellular model where it enhanced cell killing in the presence of dexamethasone via enhancing H 2 O 2 production [45, 46] . H 2 O 2 in turn was employed by MnP to catalyze S-glutathionylation of protein thiols. Such action, depicted in Scheme XI, is in essence either GPx-or thiol oxidase-like activity of MnP. Such oxidative modification has been demonstrated on both cytosolic and mitochondrial levels. In cytosol cysteine units of p50 and most so p65 of NF-kB seem to be modified, while complexes I, III and IV were S-glutathionylated in mitochondria. Also oxidation of p50 by MnP in nucleus has been suggested by Piganelli's group [48] . All proteins except complex IV (though S-glutathionylated) were inactivated by such oxidative modifications. [68] , nitroxides, curcumin [73] and flavonoids [70, 71] . In next kidney I/R study, the authors introduce N-acetyl cysteine into the GPM mixture; all effects were enhanced; note that MnP cycles with thiols producing H 2 O 2 (Scheme XI) [66, 67] . Adapted from [67] . [77] . This suggests that much about its in vivo actions awaits further clarification. In a rat spinal cord ischemia/reperfusion model, under same dosing regime, MnTBAP 3 À suppressed NF-κB expression as does a powerful SOD mimic, MnTnHex-2-PyP 5 þ . Such action prevented excessive NF-κB-driven inflammation [4] . The dose-dependence and the mechanism behind NF-κB inactivation by those MnPs are under further investigation. Adapted from [4] . and MnTnBuOE-2-PyP 5 þ in different organisms via various administration routes. The PK studies involved plasma and different organs such as liver, kidney, lungs, spinal cord, brain, spleen, heart, colon, salivary glands and tongue. Also intracellular accumulation has been addressed on ZnPs and MnPs and data published on membrane, cytosolic, nuclear, mitochondrial, endoplasmatic reticular and lysosomal accumulation [78] [79] [80] [81] [82] [83] . Largest body exposure of MnPs, expressed as AUC (area under pharmacokinetic curve) has been obtained via subcutaneous route; this route also has another advantage as it imposes the lowest acute side effects in MnP administration À blood pressure drop. Highest levels of MnPs are found in liver and kidneys (at µM levels), while the lowest were detected in brain (at nM levels). Lipophilic and cationic, MnTnHex-2-PyP 5 þ and MnTnBuOE-2-PyP 5 þ accumulate several fold more in brain (driven there by the anionic phospholipids) than does hydrophilic MnTE-2-PyP and LPS stimulated macrophages [48] . Such accumulation seems to be important given the suggestion by Tse and Piganelli that MnP oxidizes p50 in nucleus [48, 49] . Cationic MnPs were also found to favor accumulation in cell wall of E. coli due to abundance of negatively charged phospholipids [84] . Extensive distribution studies of fluorescent Zn analogs using confocal fluorescent microscopy indicate their accumulation in membranes, lysosomes and endoplasmatic reticulum also [78, 85] . The study was carried out on adenocarcinoma cells where lipophilic ZnTnHex-2-PyP 5 þ was also found in mitochondria in the vicinity of cytochrome c oxidase [79] . The only difference between Zn and
Mn analogs is the lack of single charge on Zn center. Yet, with longer alkyl analogs, such as MnTnHex-2-PyP 5 þ no difference in their lipophilicities exists as single cationic charge on Mn is shielded from the solvent by long hexyl chains. Moreover, in vivo MnPs get readily reduced with cellular reductants, lose single charge on metal site and become similarly hydrophilic as ZnPs [86] . Thus, accumulation data on ZnPs (in particular those with long alkylpyridyl substituents) can be readily applied to MnPs.
Scheme XXIV. Impact of lipophilicity on mitochondrial vs cytosolic accumulation of cationic MnPs in S. cerevisiae. Impressive levels of otherwise hydrophilic compounds were found in mitochondria relative to cytosol and are presumably due to their high penta-cationic charge. The striking impact of lipophilicity on their mitochondrial accumulation was demonstrated [91] . Even the most hydrophilic MnTM-2-PyP 5 þ and MnTE-2-PyP 5 þ prefer mitochondria to cytosol. Such data suggest that pentacationic charge, rather than lipophilicity of pyridyl alkyl chains, controls mitochondrial accumulation of MnPs.
Scheme XXV. Therapeutic effects of MnPs. The O 2 d À specific models of SOD-deficient single-cell pro-and eukaryotic organisms, E. coli and S. cerevisiae, are the first and major steps in evaluating therapeutic potential of MnPs. Once they are successfully tested in unicellular organisms, MnPs are forwarded to various cellular and animal models. During the last two decades numerous cellular and animal studies (on mice, rats, rabbits and monkeys), conducted on models of diverse diseases, support remarkable therapeutic potential of metalloporphyrins; thus we hope that some will successfully Clinical Trials. Therapeutic effects demonstrated in models of CNS injuries, immune disorders, cancer and radioprotections were summarized in several manuscripts of Forum Issue " SOD therapeutics" of Antioxidants & Redox Signaling 2014.
Scheme XXVI. MnPs undergo anti-and pro-oxidative reactions which may be demonstrated either as anti-or pro-oxidative therapeutic effects. While such reasoning and experimental data behind it have been a main theme across this review, it is important to stress it here again: researchers need to differentiate between the type of reactions of MnPs and nature of therapeutic effects they observe. For example, oxidation of cysteines of NF-kB by MnP suppresses its activation which in turn suppresses secondary oxidative stress. This is demonstrated as reduced inflammation -commonly accepted as anti-oxidative therapeutic effects. Further, the oxidation of cysteine of Keap1 by MnP would activate Nrf2 which would upregulate endogenous antioxidative defenses (catalases, SODs, peroxidases, etc) in an adaptive response. This would result in suppression of inflammation -clear case of antioxidative effect. Again pro-oxidative reaction of MnP results in anti-oxidative therapeutic effects. Please note that not all reactions thus far studied are listed in this Scheme, such as reactions with tetrahydrobiopterin, H 2 O 2 and CO 3 d À (for further information see other chapters). Many more in vivo reactions of MnPs are likely yet to be identified.
